US Patent

US7700128 — Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester

Formulation · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2027-01-30 · 1y remaining

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a solid preparation that combines an insulin sensitizer, an insulin secretagogue, and a polyoxyethylene sorbitan fatty acid ester.

USPTO Abstract

A solid preparation useful as a diabetes-treating agent or the like and excellent in the dissolution properties of an insulin sensitizer and an insulin secretagogue, which comprises an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester is provided.

Drugs covered by this patent

Patent Metadata

Patent number
US7700128
Jurisdiction
US
Classification
Formulation
Expires
2027-01-30
Drug substance claim
No
Drug product claim
Yes
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.